natgillin/translations-raw huggingface dataset:
Under field conditions, only sub-group A is infective and immunisation against sub- group A provides full protection against A, B and C.
Imunizacija proti podskupini A pa omogoča popolno zaščito proti A, B in C.
Store and transport refrigerated (2  C – 8  C) protected from light.
Zaščitite pred svetlobo.
4/ 17 6.6 Special precautions for the disposal of unused veterinary medicinal product or waste materials derived from the use of such products
4/ 17 6. 6 Posebni varnostni ukrepi za odstranjevanje neporabljenega zdravila ali odpadnih snovi
MANUFACTURER(S) OF THE BIOLOGICAL ACTIVE SUBSTANCE(S) AND MANUFACTURING AUTHORISATION HOLDER(S) RESPONSIBLE FOR BATCH RELEASE
6/ 17 A IZDELOVALEC BIOLOŠKE ZDRAVILNE UČINKOVINE (ZDRAVILNIH UČINKOVIN) IN IMETNIK DOVOLJENJA ZA IZDELAVO ZDRAVILA, ODGOVOREN ZA SPROSTITEV SERIJE
Name and address of the manufacturer(s)of the biological active substance(s)
Ime in naslov izdelovalcev biološke zdravilne učinkovine (zdravilnih učinkovin).
7/ 17 LABELLING AND PACKAGE LEAFLET
7/ 17 DODATEK III
FPV (PLI IV).....................................................................................................................  103.5 CCID 50 FeLV recombinant canarypox virus (vCP97)....................................................................  107.2 CCID 50 Gentamicin, at most..........................................................................................................................
FHV (sev F2).....................................................................................................................  104, 9 CCID 50 FCV (seva 431 in G1).......................................................................................  2, 0 enot v testu ELISA FPV (PLI IV).....................................................................................................................  103, 5 CCID 50 rekombinantni poxvirus kanarčkov, ki vsebuje antigen virusa mačje levkemije (vCP97)  107, 2 CCID 50 Gentamicin, največ...........................................................................................................................
Store and transport refrigerated (2  C – 8  C) protected from light.
Shranjujte in prevažajte pri temperaturi 2C – 8C (v hladilniku).
EU/ 2/ 04/ 048/ 001 Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/ 2/ 04/ 048/ 002 Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)
EU/ 2/ 04/ 048/ 001 Liofilizat (10 stekleničk z 1 odmerkom) in vehikel (10 stekleničk po 1 ml) EU/ 2/ 04/ 048/ 002 Liofilizat (50 stekleničk z 1 odmerkom) in vehikel (50 stekleničk po 1 ml)
Purevax RCP FeLV lyophilisate for injection
Purevax RCP FeLV liofilizat za injiciranje.
Subcutaneous route
Subkutana pot.
Purevax RCP FeLV Lyophilisate and solvent for suspension for injection.
Purevax RCP FeLV Liofilizat in vehikel za suspenzijo za injiciranje
Attenuated feline panleucopenia virus (PLI IV)............................................................  103.5 CCID 50 1 Excipient:
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2)............................................  104, 9 CCID 50 1 Inaktivirani antigeni kalici virusamačk (seva FCV 431 in G1)........................  2, 0 enot v testu ELISA Atenuiran virus panleukopenije mačk (PLI IV).............................................................  103, 5 CCID 50 1 Pomožna snov:
FeLV recombinant canarypox virus (vCP97).................................................................  107.2 CCID 50 1 1: cell culture infective dose 50%
50% infektivni odmerek za celično kulturo
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components, and 2 weeks after primary vaccination course for feline leukaemia component.
Imunost proti levkemiji mačk nastopi dva tedna po osnovnem cepljenju.
The duration of immunity is 1 year after the last (re-)vaccination for rhinotracheitis, calicivirus and feline leukaemia components, and 3 years for panleucopenia component.
15/ 17 Živali so po zadnjem cepljenju 1 leto odporne proti kužnemu rinotraheitisu, okužbam s kalicivirusi in leukemiji mačk ter tri leta proti mačji panleukopeniji.
Inject by subcutaneous route one 1 ml dose of vaccine after reconstitution of the lyophilisate with the solvent, according to the following vaccination schedule:
Po rekonstituciji liofilizirane sestavine z vehiklom injicirajte 1 ml odmerek cepiva v podkožje, po naslednjem razporedu:
- first injection: from 8 weeks of age;
- prva injekcija od osmega tedna starosti naprej,
- for all components one year after primary vaccination course;
- eno leto po osnovnem cepljenju
Do not mix with any other vaccine or immunological product.
Ne mešajte z drugimi cepivi ali imunološkimi proizvodi.
Attenuated feline panleucopenia virus (PLI IV)............................................................. ≥ 103.5 CCID501 Excipient:
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2)............................................  104, 9 CCID 50 1 Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in G1).........................  2, 0 enot v testu ELISA Atenuiran virus panleukopenije mačk (PLI IV).............................................................  103, 5 CCID 50 1 Pomožna snov:
16.5 µg Solvent:
16. 5 µg Vehikel:
Water for injection....................................................................................................................... q. s.
Voda za injiciranje......................................................................................................................... q. s.
1 ml 1: cell culture infective dose 50% For a full list of excipients, see section 6.1.
50% infektivni odmerek za celično kulturo
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components.
Imunost proti kužnemu rinotraheitisu, kalicivirusu mačk in mačji panleukopeniji nastopi 1 teden po osnovnem cepljenju.
The duration of immunity is 1 year after the last (re-)vaccination for rhinotracheitis and calicivirus, and 3 years for panleucopenia component.
Živali so po zadnjem cepljenju eno leto odporne proti kužnemu rinotraheitisu in okužbam s kalicivirusi ter tri leta proti mačji panleukopeniji.
Inject by subcutaneous route one 1-ml dose of vaccine after reconstitution of the lyophilisate with the solvent, according to the following vaccination schedule:
Po rekonstituciji liofilizirane sestavine z vehiklom injicirajte 1- ml odmerek cepiva v podkožje, po naslednjem razporedu:
- for all components one year after primo-vaccination,
- vseh sestavin cepiva eno leto po osnovnem cepljenju
- then every year for the rhinotracheitis and calicivirosis components, and every three years
Cepljenje proti
for the panleucopenia component.
panleukopeniji ponavljamo vsaka tri leta.
No effects other than those already mentioned in section “ Adverse reactions” have been observed, except hyperthermia that may exceptionally last 5 days.
Izjemoma lahko povišana temperatura traja pet dni.
3/ 17 4.11 Withdrawal period(s)
4. 11 Karenca( e)
QI06AH09
Oznaka ATC vet: QI06AH09
FPV (PLI IV)..................................................................................................................... ≥ 103.5 CCID50 Gentamicin, at most.......................................................................................................................
FHV (sev F2).....................................................................................................................  104, 9 CCID 50 FCV (seva 431 in G1).......................................................................................  2, 0 enot v testu ELISA FPV (PLI IV).....................................................................................................................  103, 5 CCID 50 Gentamicin, največ........................................................................................................................
EU/ 2/ 04/ 052/ 001 Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/ 2/ 04/ 052/ 002 Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)
EU/ 2/ 04/ 052/ 001 Liofilizat (10 stekleničk z 1 odmerkom) in vehikel (10 stekleničk po 1 ml) EU/ 2/ 04/ 052/ 002 Liofilizat (50 stekleničk z 1 odmerkom) in vehikel (50 stekleničk po 1 ml)
Purevax RCP lyophilisate for injection
Purevax RCP liofilizat za injiciranje.
Purevax RCP lyophilisate and solvent for suspension for injection.
Purevax RCP liofilizat in vehikel za suspenzijo za injiciranje
MERIAL Laboratoire Porte des Alpes Rue de l’ aviation F-69800 Saint-Priest France
Imetnik dovoljenja za proizvodnjo zdravila, odgovoren za sprostitev serije MERIAL Laboratoire Porte des Alpes Rue de l' Aviation F- 69800 Saint Priest Francija
Attenuated feline panleucopenia virus (PLI IV)............................................................. ≥ 103.5 CCID501 Excipient:
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2)............................................  104, 9 CCID 50 1 Inaktivirani antigeni kalici virusamačk (seva FCV 431 in G1)........................  2, 0 enot v testu ELISA Atenuiran virus panleukopenije mačk (PLI IV).............................................................  103, 5 CCID 50 1 Pomožna snov:
Water for injection q. s.
Voda za injiciranje........................................................................................................................ q. s.
1 ml 1: cell culture infective dose 50%
50% infektivni odmerek za celično kulturo
Onsets of immunity have been demonstrated 1 week after primary vaccination course for rhinotracheitis, calicivirus and panleucopenia components.
Imunost proti kužnemu rinotraheitisu, kalicivirozi mačk in mačji panleukopeniji nastopi 1 teden po osnovnem cepljenju.
The duration of immunity is 1 year after the last (re-)vaccination for rhinotracheitis and calicivirus, and 3 years for panleucopenia component.
Živali so po zadnjem cepljenju1 eno leto odporne proti kužnemu rinotraheitisu in okužbam s kalicivirusi ter tri leta proti mačji panleukopeniji.
- for all components one year after the primary vaccination course,
- eno leto po osnovnem cepljenju
Safety and efficacy data are available which demonstrate that this vaccine can be mixed with Merial non-adjuvanted vaccine against feline leukaemia and/ or administered the same day but not mixed with Merial adjuvanted vaccine against rabies.
Podatki o varnosti in učinkovitosti dokazujejo, da se lahko cepivo uporablja sočasno z Merialovim neadjuviranim cepivom proti mačjji levkemiji in/ ali se ga lahko uporabi isti dan kot Merialovo adjuvirano cepivo proti steklini, vendar se ga ne sme mešati z omenjenim cepivom.
Excipient:
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2)............................................. ≥ 104, 9 CCID501 Inaktivirani antigeni kalici virusa mačk (sev FCV 431 in G1)......................... ≥ 2, 0 enot v testu ELISA Pomožna snov:
Gentamicin, at most..................................................................................................................... .16.5 µg Solvent:
16. 5 µg Vehikel:
- against calicivirus infection to reduce clinical signs and excretion.
- Proti okužbam s kalicivirusi, za ublažitev kliničnih znamenj in zmanjšanje izločanja virusov.
The duration of immunity is 1 year after the last (re-)vaccination.
Imunost proti kužnemu rinotraheitisu in kalicivirusu mačk nastopi 1 teden po osnovnem cepljenju.
4.5 Special precautions for use
2/ 17 4. 5 Posebni previdnostni ukrepi
QI06AH08
Oznaka ATC vet: QI06AH08
9/ 17 PARTICULARS TO APPEAR ON THE OUTER PACKAGE {NATURE/ TYPE}
9/ 17 PODATKI NA ZUNANJI OVOJNINI
Gentamicin, at most......................................................................................................................
FHV (sev F2)..................................................................................................................... ≥ 104, 9 CCID50 FCV (seva 431 in G1)....................................................................................... ≥ 2, 0 enot v testu ELISA Gentamicin, največ........................................................................................................................
EU/ 2/ 04/ 051/ 001 Lyophilisate (10 bottles of 1 dose) + solvent (10 bottles of 1 ml) EU/ 2/ 04/ 051/ 002 Lyophilisate (50 bottles of 1 dose) + solvent (50 bottles of 1 ml)
EU/ 2/ 04/ 0451/ 001 Liofilizat (10 stekleničk z 1 odmerkom) in vehikel (10 stekleničk po 1 ml) EU/ 2/ 04/ 051/ 002 Liofilizat (50 stekleničk z 1 odmerkom) in vehikel (50 stekleničk po 1 ml)
Purevax RC lyophilisate for injection
Purevax RC liofilizat za injiciranje.
Marketing authorisation holder MERIAL 29, avenue Tony Garnier F-69007 Lyon France
Imetnik dovoljenja za promet z zdravilom MERIAL 29, avenue Tony Garnier F- 69007 Lyon Francija
Manufacturing authorisation holder responsible for batch release MERIAL Laboratoire Porte des Alpes Rue de l'Aviation F-69800 Saint Priest France
Imetnik dovoljenja za proizvodnjo zdravila, odgovoren za sprostitev serije MERIAL Laboratoire Porte des Alpes Rue de l' Aviation F- 69800 Saint Priest Francija
Purevax RC Lyophilisate and solvent for suspension for injection.
Purevax RC Liofilizat in vehikel za suspenzijo za injiciranje
Excipient:
Atenuirani herpes virus rinotraheitisa mačk (sev FHV F2)............................................. ≥ 104, 9 CCID501 Inaktivirani antigeni kalici virusamačk (seva FCV 431 in G1)........................ ≥ 2, 0 enot v testu ELISA Pomožna snov:
Water for injection..................................................................................................................... q. s.
1ml 1:
- second injection:
- prva injekcija od osmega tedna starosti naprej,
Quadrisol is an oral gel presented in graduated multidose oral syringes that contain the active substance vedaprofen as 100 mg/ ml (for horses).
Zdravilo Quadrisol je peroralni gel v graduirani večodmerni peroralni brizgi, ki vsebuje zdravilno učinkovino vedaprofen v jakostih 100 mg/ ml (za konje).
In horses, Quadrisol 100 mg/ ml oral gel is used to relieve pain and reduce inflammation due to problems with and injury to the muscles, bones and joints and also injuries to other non-bony areas of the body(so called soft tissue lesions) including the trauma caused by surgery.
Pri konjih uporabljamo peroralni gel Quadrisol 100 mg/ ml za zmanjšanje vnetja in bolečine zaradi težav z mišicami, kostmi in sklepi ter poškodb teh struktur in zaradi poškodb drugih nekostnih delov telesa (t. i. poškodb mehkih tkiv), med drugim zaradi kirurških posegov.
For details, please see the Package Leaflet.
Za podrobnosti glejte Navodilo za uporabo.
Quadrisol contains vedaprofen, which belongs to a class of medicines called non-steroidal anti-inflammatory drugs (NSAIDs).
Zdravilo Quadrisol vsebuje vedaprofen, ki spada v skupino zdravil, ki jih imenujemo nesteroidna protivnetna zdravila (NSAID).
What benefit has Quadrisol shown during the studies?
Kako je bilo zdravilo Quadrisol raziskano?
Quadrisol oral gel improved the clinical scores for lameness and soft tissue injuries in horses.
Zdravilo Quadrisol (peroralni gel) so preučili na veliko konjih s težavami s kostmi, mišicami, drugimi mehkimi tkivi in sklepi.
The response to treatment with Quadrisol was similar to the response to the other similar product.
Peroralni gel Quadrisol je izboljšal klinične rezultate za šepavost in poškodbe mehkih tkiv pri konjih.
Horses intended for racing and competition should be treated according to local requirements and appropriate precautions must be taken to ensure compliance with the official competition regulations.
Upoštevajte previdnostne ukrepe za skladnost z uradnimi pravili tekmovanja.
The Committee for Medicinal Products for Veterinary Use (CVMP) agreed that the benefits of Quadrisol to reduce of inflammation and relieve pain caused by musculoskeletal disorders and trauma are greater than any risks associated with this treatment.
Odbor za zdravila za uporabo v veterinarski medicini (CVMP) je mnenja, da so koristni učinki zdravila Quadrisol pri zmanjšanju in lajšanju vnetja in bolečine zaradi mišično- skeletnih bolezni ter travmatskih poškodb večji od z njim povezanih tveganj.
Other information about Quadrisol:
©EMEA 2009 Druge informacije o zdravilu Quadrisol:
The European Commission granted a marketing authorisation valid throughout the European Union, for Quadrisol to Intervet International B. V. on 16 July 1997.
Evropska komisija je dovoljenje za promet z zdravilom Quadrisol, veljavno po vsej Evropski uniji, odobrila družbi Intervet International B. V. dne 16. julija 1997.
Later approval was given for the oral use in dogs (February 1999) and a solution for injection for horses (November 1999); however, in August 2008 the Marketing Authorisation Holder withdrew these presentations for commercial reasons.
Kasneje je bila odobrena peroralna uporaba za pse (feburarja 1999) in raztopina za injiciranje za konje (novembra 1999).
Information on the prescription status of this product may be found on the label of the carton box that contains the product.
Vendar pa je imetnik dovoljenja za promet v avgustu 2008 obe odobreni uporabi zaradi komercialnih razlogov umaknil. Podatke o statusu predpisovanja tega zdravila najdete na nalepki na škatli zdravila.
This summary was last updated in December 2008.
Ta povzetek je bil nazadnje posodobljen 12- 2008.
Oral gel
peroralni gel
EU/ 2/ 97/ 005/ 005 QUADRISOL 100 mg/ ml
EU/ 2/ 97/ 005/ 005 QUADRISOL
Quadrisol 100 mg/ ml oral gel for horses
Quadrisol 100 mg/ ml, peroralni gel za konje
Each ml of Quadrisol oral gel contains:
1 ml peroralnega gela Quadrisol vsebuje:
Propylene glycol:
Propilenglikol
Reduction of inflammation and relief of pain associated with musculo-skeletal disorders and soft tissue lesions (traumatic injuries and surgical trauma).
Če je kirurška travma pričakovana, lahko dajemo Quadrisol profilaktično najmanj 3 ure pred operativnim posegom.
In cases of anticipated surgical trauma, Quadrisol can be given prophylactically at least 3 hours prior to elective surgery.
4. 3 Kontraindikacije
Do not use in lactating mares.
Ne uporabljajte pri kobilah v obdobju laktacije.
Do not use in the case of hypersensitivity to the active substance or to any of the excipients.
Ne uporabite v primeru preobčutljivosti na zdravilno učinkovino ali na katero koli pomožno snov.
Horses with oral lesions should be assessed clinically and the attending veterinarian should take a decision as to whether treatment should be continued.
Pri konjih s poškodbami v ustni votlini je treba stanje klinično oceniti, veterinar pa mora odločiti o nadaljevanju zdravljenja.
Avoid use in any dehydrated, hypovolaemic or hypotensive animals, as there may be potential risk of increased renal toxicity.
Uporabi zdravila se je treba izogibati pri dehidriranih, hipovolemičnih ali hipotenzivnih živalih, ker se pri njih lahko poveča nevarnost toksičnih učinkov na ledvice.
The safety of the veterinary medicinal product has not been established during lactation
Varnost zdravila med laktacijo ni raziskana.
Quadrisol must not be given with other NSAIDs or glucocorticosteroids.
Quadrisola ne smemo dajati hkrati z drugimi nesteroidnimi protivnetnimi zdravili (NSAID) ali glukokortikosteroidi.
Twice daily administration.
Za peroralno dajanje Zdravilo dajemo 2- krat na dan.
An initial dose of 2 mg/ kg (2.0 ml/ 100 kg) is followed by a maintenance dose of 1 mg/ kg (1.0 ml/ 100 kg) given every 12 hours.
Začetni odmerek je 2 mg/ kg (2, 0 ml/ 100 kg), nato dajemo vzdrževalni odmerek po 1 mg/ kg (1, 0 ml/ 100 kg) vsakih 12 ur.
Bodyweight and dosage must be accurately determined to avoid overdosing.
Da bi se izognili prevelikemu odmerjanju, je treba natančno določiti telesno maso.
Lesions and bleedings in the alimentary tract, diarrhoea, urticaria, lethargy, inappetence.
Pojavijo se lahko poškodbe in krvavitve v prebavilih, driska, urtikarija, letargija in zmanjšan tek.
If symptoms occur, treatment should be discontinued.
Če se pojavijo ti simptomi, je treba zdravljenje prekiniti.
3 4.11 Withdrawal period(s)
4. 11 Karenca
12 days Not permitted for use in lactating animals producing milk for human consumption.
12 dni Zdravila ne smemo dajati živalim v obdobju laktacije, katerih mleko je namenjeno za prehrano človeka.
ATCvet code:
Farmakoterapevtska skupina: nesteroidno protivnetno zdravilo Oznaka ATCvet:
5.1 Pharmacodynamic properties
3 5. 1 Farmakodinamične lastnosti
Vedaprofen is a non-steroidal anti-inflammatory drug (NSAID) belonging to the propionic acid derivate group.
Vedaprofen je nesteroidno protivnetno zdravilo (NSAID) iz skupine derivatov aril- propionske kisline.
Vedaprofen contains an asymmetric carbon atom and, therefore, is a racemic mixture of a (+) enantiomer and a (-) enantiomer.
Raziskave pri konjih so pokazale, da močno zavira sintezo prostaglandina E2 (Pg E2) v eksudatu in sintezo tromboksana B2 v serumu in eksudatu. Vsebuje nesimetrični ogljikov atom in je zato racemna zmes (+) enantiomera in (-) enantiomera.
Bioavailability after oral administration is 80-90%, but is reduced significantly if medication is administered with food.
Njegova biološka uporabnost po peroralnem dajanju je 80 do 90% vendar pa je znatno manjša, če zdravilo dajemo ob obroku hrane.
Approximately 70% of an orally administered dose is excreted in the urine.
Približno 70% peroralno vnesenega odmerka se izloči z urinom.
Water (minimum purified grade), Propylene glycol, Hydroxyethylcellulose, Potassium hydroxide (E525), Hydrochloric acid Chocolate flavour.
voda (najmanj prečiščene kakovosti) propilenglikol hidroksietilceluloza kalijev hidroksid (E525) klorovodikova kislina čokoladna aroma
The syringe is fitted with variable dose capability, adjustable in steps of 0.5 ml and graduated to 1 ml.
Brizga ima oznake po 1 ml in je opremljena z nastavkom za različne odmerke, ki jih lahko prilagajamo v stopnjah po 0, 5 ml.
The product is presented as a single syringe in a carton box or as a multipack of 3 syringes in a carton box.
Na voljo so zloženke z eno brizgo ali tremi brizgami.
4 December 1997 / 13 November 2007
4. december 1997 / 13. november 2007
Rue de Lyons F – 27460 Igoville France
Rue de Lyons F – 27460 Igoville Francija
Not applicable.
Navedba ni smiselna..
Vedaprofen is included in Annex I of Council Regulation (EEC) No 2377/ 90 in accordance with the following table:
2377/ 90, kot je navedeno v tabeli:
MRLs
Najvišje dovoljene količine Ciljna tkiva zaostankov (MRL)
Target tissues Other provisions
Druge določbe
Equidae
vedaprofen kopitarji
1000 µg/ kg Kidney 100 µg/ kg Liver 50 µg/ kg Muscle 20 µg/ kg Fat
1000 µg/ kg ledvice 100 µg/ kg jetra 50 µg/ kg mišice 20 µg/ kg maščevje
Excipients are included in Annex II of Council Regulation (EEC) No.
Pomožne snovi so vključene v Dodatek II Uredbe Sveta (ES) št.
2377/ 90 in accordance with the following table:
2377/ 90 kot je navedeno v tabeli:
Other provisions
Živalska vrsta
All food producing species
Druge določbe
1 OJ No.
kalijev hidroksid (E525) 1
L 272 of 25.10.96
L 272 of 25. 10. 96 2 OJ No.
7 Hydrochloric acid Propylene glycol2
7 DODATEK III
Council Regulation 2377/ 90.
OZNAČEVANJE IN NAVODILO ZA UPORABO
LABELLING AND PACKAGE INSERT
OZNAČEVANJE
100 mg/ ml oral gel for horses
100 mg/ ml, peroralni gel za konje
Oral gel.
Peroralni gel
Adjustable dose syringe, containing 30 ml gel (EU/ 2/ 97/ 005/ 001) 3 adjustable dose syringes, each containing 30 ml gel (EU/ 2/ 97/ 005/ 005)
Brizga z nastavljivo velikostjo odmerka po 30 ml gela (EU/ 2/ 97/ 005/ 001) 3 brizge z nastavljivo velikostjo odmerka po 30 ml gela (EU/ 2/ 97/ 005/ 005)
TARGET SPECIES
CILJNAE ŽIVALSKE VRSTE
Horse.
Konji
Reduction of inflammation and relief of pain.
Zmanjšanje vnetja in bolečine
For oral use.
Za peroralno dajanje
12 days Not permitted for use in lactating animals producing milk for human consumption.
12 dni Zdravila ne smemo dajati kobilam v obdobju laktacije, katerih mleko je namenjeno za prehrano človeka.
If side effect occurs, treatment should be discontinued.
Če se pojavijo stranski učinki, moramo zdravljenje prekiniti.
Do not use in lactating animals.
Ne uporabite v obdobju laktacije.
For full contra-indications, see package insert.
Podrobni podatki o kontraindikacijah so v priloženem navodilu.